The Benchmark Company

LIVINGSTON, N.J.--(BUSINESS WIRE)-- Columbia Laboratories, Inc. (Nasdaq: CBRX) has raised approximately $11,772,000 in gross proceeds to the Company through the sale of 10,900,000 shares of its common stock and warrants to purchase 5,450,000 shares of its common stock in a registered direct offering. The common stock and warrants were sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.5 shares of common stock at a price of $1.08 per unit in a registered direct offering. The warrants will be exercisable at an exercise price of $1.52 per share of common stock at ...

LIVINGSTON, N.J.--(BUSINESS WIRE)-- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that it has priced a transaction to raise up to approximately $11,772,000 through the sale of up to approximately 10,900,000 shares of its common stock and warrants to purchase 5,450,000 shares of its common stock in a registered direct offering. The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.5 shares of common stock. Each unit will be sold at a negotiated price of $1.08 per unit. Net proceeds are expected to be up to ...

SANTA CLARA, Calif., Sept. 18 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, today announced that it closed a private placement financing with institutional and other accredited investors, including members of NewCardio's management team and board of directors, who purchased over half of the offering. Gross proceeds of approximately $2.9 million were generated through the issuance of approximately 2,900 shares of a new Series C Convertible Preferred Stock at $1,000 per share and convertible into approximately 2.9 million common shares, together with approximately 2.9 million common stock purchase warrants having an exercise price per share of $1.20. The Benchmark Company LLC served as the placement agent, who engaged Hallmark Investments as a selected dealer in this transaction. Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "The successful completion of this transaction, despite the difficult economic conditions and the challenges small companies face in securing additional ...

Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that it has priced a transaction to raise up to approximately $4.7 million through the sale of up to approximately 1.3 million shares of ...

Benchmark Company initiates coverage on AvalonBay Communities (NYSE: AVB) with a Hold rating.

The firm calls AvalonBay the best in breed stock within the residential REIT industry ...